H. Kubra Elcioglu, Caglar Guvel and Levent Kabasakal
Posters: J Diabetes Metab
Our aim in this study was to investigate the role of caveolin-1 on functional changes caused by insulin resistance in aorta and corpus cavernosum tissues of fructose diabetic rats, and to investigate whether genistein or insulin treatment have any protective effect on these parametres. For this purpose male Sprague-Dawley ratswere divided into 2 groups; Control and fructose groups. Control groupconsisted of no treatmentgroup? andgenistein(G) groups. To induce diabetes %10 fructose was administered in drinking water for 8 weeks and diabetic animals were divided into 4 subgroups: a) Genisteingroup (FG) (n=6) treated with genistein (1 mg/kg/day), b) Insulingroup (FI) (n=6) treatedwith 6U/kg/dayinsulin c) group (n=6), insulinandgenisteinwereadministered in combinationfor 8 weeks; and D) notreatmentdiabeticgroup (n=6) (F. At the end of the experimental period the animals were decapitated andcorpus covernosum tissues amples were collected, they were used for in vitrostudies or stored in liquidnitrogen for Western-blotanalysis and histologial investigations. Endothelium dependent relaxation andcontraction responses in the corpus cavernosum tissues were significantly attenuated in thediabetic group. Relaxation andcontractile responses were restored after treatment withinsulin, genistein ori nsulin and genistein in combination. Caveolin -1 expression that was increased in diabetic animals was also decreased after all treatment, suggesting that the detoriation of the vascular responses in diabetic animals is related to an increase in Caveolin -1 expression.
H. Kubra Elcioglu has completed his Ph.D. at the age of 31 years from Marmara University and postdoctoral studies from Marmara University School of Pharmacy, Department of Pharmacology. She is the associated professor in Pharmacology and also Vice Dean of Marmara University School of Pharmacy. She has published more than 13 papers in reputed journals. She is the member of Turkish Pharmacological and Clinical Pharmacy Societies.
